Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
SLP - Simulations Plus, Inc.
Market Cap 1.02B P/E 102.14 EPS this Y -2.00% Ern Qtrly Grth -21.70%
Income 9.64M Forward P/E 69.01 EPS next Y 31.30% 50D Avg Chg 11.00%
Sales 66.98M PEG 4.32 EPS past 5Y -4.57% 200D Avg Chg 21.00%
Dividend N/A Price/Book 6.01 EPS next 5Y 15.00% 52W High Chg -24.00%
Recommedations 1.70 Quick Ratio 11.73 Shares Outstanding 20.01M 52W Low Chg 57.00%
Insider Own 18.37% ROA 3.63% Shares Float 16.32M Beta 0.70
Inst Own 75.11% ROE 5.51% Shares Shorted/Prior 1.16M/1.34M Price 51.07
Gross Margin 72.53% Profit Margin 14.40% Avg. Volume 101,696 Target Price 57.00
Oper. Margin 10.14% Earnings Date Oct 23 Volume 93,257 Change 0.77%
Healthcare | Health Information Services | United States
About Simulations Plus, Inc.

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, RENAsym, IPFsym, and MITOsym products. In addition, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, it offers creative and insightful consulting services to support its quantitative systems pharmacology/quantitative systems toxicology modelling. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.

Simulations Plus, Inc. News
12/17/24 Simulations Plus Announces First Quarter Fiscal Year 2025 Earnings and Conference Call Date
12/13/24 US Growth Stocks With High Insider Ownership For December 2024
12/05/24 Simulations Plus, Inc.'s (NASDAQ:SLP) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
11/26/24 Wall Street Analysts Predict a 56.99% Upside in Simulations Plus (SLP): Here's What You Should Know
11/22/24 Simulations Plus (SLP) Stock Jumps 8.9%: Will It Continue to Soar?
11/19/24 Simulations Plus to Participate in the BTIG Digital Health Forum
11/14/24 US Growth Stocks With High Insider Ownership Seeing Up To 115% Earnings Growth
11/13/24 Simulations Plus and the University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables
11/12/24 Salesforce.com (CRM) Moves 6.1% Higher: Will This Strength Last?
11/08/24 How Much Upside is Left in Simulations Plus (SLP)? Wall Street Analysts Think 77.52%
11/07/24 We Think Simulations Plus' (NASDAQ:SLP) Solid Earnings Are Understated
11/06/24 Simulations Plus to Participate in the Stephens Annual Investment Conference
10/25/24 Simulations Plus Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
10/24/24 Q4 2024 Simulations Plus Inc Earnings Call
10/24/24 Simulations Plus' Q4 Earnings Top Estimates on Solid Revenue Growth
10/24/24 High Growth Tech Stocks to Watch in October 2024
10/24/24 Simulations Plus Inc (SLP) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amid Market ...
10/23/24 Simulations Plus (SLP) Surpasses Q4 Earnings Estimates
10/23/24 Simulations Plus: Fiscal Q4 Earnings Snapshot
10/23/24 Simulations Plus Reports Fourth Quarter and Fiscal 2024 Financial Results
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
WOLTOSZ WALTER S Director Director Feb 01 Sell 38.04 20,000 760,800 3,640,195 02/05/24
Paglia John Kenneth Director Director Jan 04 Sell 43.74 1,000 43,740 2,097 01/04/24
WOLTOSZ WALTER S Director Director Jan 02 Sell 44.67 20,000 893,400 3,659,403 01/04/24
DiBella John Anthony II Business Unit Presid.. Business Unit President Dec 22 Sell 45.16 5,411 244,361 79,840 12/26/23
DiBella John Anthony II Business Unit Presid.. Business Unit President Dec 22 Option 19.81 5,411 107,192 85,251 12/26/23
WOLTOSZ WALTER S Director Director Dec 01 Sell 38.79 60,000 2,327,400 3,764,403 12/05/23
Paglia John Kenneth Director Director Jul 13 Sell 46.45 1,200 55,740 2,644 07/17/23
WOLTOSZ WALTER S Director Director Apr 26 Sell 41.8 20,000 836,000 3,875,739 04/27/23
DiBella John Anthony II Division President Division President Mar 23 Option 6.85 35,000 239,750 79,840 03/24/23
FREDERICK WILLIAM W CFO CFO Mar 02 Option 37.89 1,875 71,044 1,875 03/06/23
WOLTOSZ WALTER S Director Director Feb 24 Sell 38.47 20,000 769,400 3,915,739 02/27/23
WOLTOSZ WALTER S Director Director Jan 27 Sell 39.93 20,000 798,600 3,935,010 01/31/23
WOLTOSZ WALTER S Director Director Nov 28 Sell 40.36 20,000 807,200 4,070,010 11/29/22
WOLTOSZ WALTER S Director Director Oct 27 Sell 42.36 20,000 847,200 4,089,307 10/31/22
WOLTOSZ WALTER S Director Director Sep 28 Sell 49.46 20,000 989,200 4,077,907 09/29/22
WOLTOSZ WALTER S Director Director Aug 29 Sell 61.45 20,000 1,229,000 4,097,907 08/31/22
WOLTOSZ WALTER S Director Director Jul 27 Sell 61.25 20,000 1,225,000 4,117,634 07/29/22
WOLTOSZ WALTER S Director Director Mar 29 Sell 48.93 20,000 978,600 4,197,259 03/31/22
WOLTOSZ WALTER S Director Director Feb 24 Sell 37.83 20,000 756,600 4,217,259 02/28/22
WOLTOSZ WALTER S Director Director Jan 27 Sell 39.66 20,000 793,200 4,236,830 01/28/22
Paglia John Kenneth Director Director Jan 25 Sell 40.76 600 24,456 616 01/26/22
WOLTOSZ WALTER S Director Director Sep 01 Sell 44.33 1,497 66,362 4,416,483 09/01/21
WOLTOSZ WALTER S Director Director Aug 31 Sell 44.78 18,503 828,564 4,417,980 08/31/21
- - - Apr 01 Sell 60.24 24,000 1,445,760 4,527,835 04/01/21
Paglia John Kenneth Director Director Jan 29 Option 16.03 16,500 264,495 14,968 01/29/21
Paglia John Kenneth Director Director Jan 29 Sell 80.67 17,068 1,376,876 01/29/21
WEINER DANIEL L Director Director Jan 29 Option 24.37 4,416 107,618 9,583 01/29/21